The most common adverse events were non-pulmonary infections ( @ of @ events in the azithromycin group vs @ of @ events in the placebo group ) and bronchiectasis-related events ( episodes or investigations ; @ of @ events in the azithromycin group vs @ of @ events in the placebo group ) ; however , study drugs were well tolerated with no serious adverse events being attributed to the intervention .